The regulatory environment has become increasingly supportive of multi-indication development.
Simon Bruce
Advertisement
Articles by Simon Bruce
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults
3
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial
4
Your Questions Answered: The Biggest Pharma and Biotech Stories This Week
5